Mechanisms of fosfomycin resistance in carbapenem-resistant Enterobacter sp.

International Journal of Antimicrobial Agents

Volumn 50, Issue 5, 2017, Pages 690-692

  White, Bryan P ^a,d   Stover, Kayla R ^b,c   Barber, Katie E ^b   Galloway, Regina C ^c   Sullivan, Donna C ^c   King, S Travis ^b,c  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d Oklahoma University   (United States)

Author keywords

Antibiotic resistance; Antimicrobial activity; Antimicrobial agents; Beta lactamases; Clinical therapeutics; Gram negative bacteria

Indexed keywords

FOSFOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CONTROLLED STUDY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FOSA3 GENE; FOSC2 GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; DRUG EFFECT; ENTEROBACTER; ENZYMOLOGY; GENETICS; HUMAN; ISOLATION AND PURIFICATION; PROSPECTIVE STUDY; SECRETION (PROCESS);

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; ENTEROBACTER; FOSFOMYCIN; GENES, BACTERIAL; HUMANS; PROSPECTIVE STUDIES;

EID: 85031319321     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2017.05.010     Document Type: Article

References (20)

1. Keating, G.M., Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs 73 (2013), 1951–1966.
2. Pontikis, K., Karaiskos, I., Bastani, S., Dimopoulos, G., Kalogirou, M., Katsiari, M., et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 43 (2014), 52–59.
3. Michalopoulos, A., Virtzili, S., Rafailidis, P., Chalevelakis, G., Damala, M., Falagas, M.E., Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 16 (2010), 184–186.
4. European Committee on Antimicrobial Susceptibility Testing, Breakpoint tables for interpretation of MICs and zone diameters. Available from http://www.eucast.org, 2016. (Accessed 2 May 2017)
5. Clinical and Laboratory Standards Institute, Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing: Twenty-fourth informational supplement, vol. 34, 2014, Wayne, PA, Clinical and Laboratory Standards Institute M100-S24.
6. Castañeda-García, A., Blázquez, J., Rodríguez-Rojas, A., Molecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistance. Antibiotics (Basel) 2 (2013), 217–236.
7. Liu, C., Qin, S., Xu, H., Xu, L., Zhao, D., Liu, X., et al. New Delhi Metallo-beta-lactamase 1(NDM-1), the dominant carbapenemase detected in carbapenem-resistant Enterobacter cloacae from Henan Province, China. PLoS ONE, 10, 2015 e0135044.
8. Li, Y., Zheng, B., Li, Y., Zhu, S., Xue, F., Liu, J., Antimicrobial susceptibility and molecular mechanisms of fosfomycin resistance in clinical Escherichia coli isolates in mainland China. PLoS ONE, 10, 2015 e0135269.
9. Wachino, J., Yamane, K., Suzuki, S., Kimura, K., Arakawa, Y., Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. Antimicrob Agents Chemother 54 (2010), 3061–3064.
10. Alrowais, H., McElheny, C.L., Spychala, C.N., Sastry, S., Guo, Q., Butt, A.A., et al. Fosfomycin resistance in Escherichia coli, Pennsylvania, USA. Emerg Infect Dis 21 (2015), 2045–2047.
11. Tseng, S.P., Wang, S.F., Kuo, C.Y., Huang, J.W., Hung, W.C., Ke, G.M., et al. Characterization of fosfomycin resistant extended-spectrum beta-lactamase-producing Escherichia coli isolates from human and pig in Taiwan. PLoS ONE, 10, 2015 e0135864.
12. Qin, S., Fu, Y., Zhang, Q., Qi, H., Wen, J.G., Xu, H., et al. High incidence and endemic spread of NDM-1-positive Enterobacteriaceae in Henan Province, China. Antimicrob Agents Chemother 58 (2014), 4275–4282.
13. Poirel, L., Walsh, T.R., Cuvillier, V., Nordmann, P., Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis 70 (2011), 119–123.
14. Hou, J., Huang, X., Deng, Y., He, L., Yang, T., Zeng, Z., et al. Dissemination of the fosfomycin resistance gene fosA3 with CTX-M beta-lactamase genes and rmtB carried on IncFII plasmids among Escherichia coli isolates from pets in China. Antimicrob Agents Chemother 56 (2012), 2135–2138.
15. Takahata, S., Ida, T., Hiraishi, T., Sakakibara, S., Maebashi, K., Terada, S., et al. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int J Antimicrob Agents 35 (2010), 333–337.
16. Pogue, J.M., Marchaim, D., Abreu-Lanfranco, O., Sunkara, B., Mynatt, R.P., Zhao, J.J., et al. Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008–10. J Antibiot (Tokyo) 66 (2013), 625–627.
17. Alexander, B.T., Marschall, J., Tibbetts, R.J., Neuner, E.A., Dunne, W.M. Jr, Ritchie, D.J., Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort. Clin Ther 34 (2012), 1314–1323.
18. Endimiani, A., Patel, G., Hujer, K.M., Swaminathan, M., Perez, F., Rice, L.B., et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother 54 (2010), 526–529.
19. Lu, C.L., Liu, C.Y., Huang, Y.T., Liao, C.H., Teng, L.J., Turnidge, J.D., et al. Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob Agents Chemother 55 (2011), 4295–4301.
20. Kaase, M., Szabados, F., Anders, A., Gatermann, S.G., Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany. J Clin Microbiol 52 (2014), 1893–1897.